



82<sup>E</sup>

CONGRÈS

11-12 OCTOBRE 2019

SALLE 14 - LE COUVENT DES JACOBINS  
20 PLACE SAINT-ANNE - 35000 RENNES



SOCIÉTÉ DE  
RHUMATOLOGIE  
DE L'OUEST

## « Bouillon de Culture »

*Pour une meilleure compréhension et un meilleur diagnostic  
de l'arthrite septique sur articulation native*

CENTRE DE RÉFÉRENCE  
POUR LES INFECTIONS OSTéo-ARTICULAIRES COMPLEXES  
DU GRAND OUEST

**CRIOGO**

**numecan**  
nutrition • métabolismes • cancer

Instituts  
thématiques


**Inserm**  
U-1241  
Unité CIMIAD

Institut national  
de la santé et de la recherche médicale

**CHU**  
**Rennes**

PÔLE LOCOMOTEUR  
SERVICE DE RHUMATOLOGIE  
Professeur Aleth Perdriger


**Dr Guillaume COIFFIER**  
Praticien Hospitalier  
Service de Rhumatologie  
CHU RENNES




Ostéo-arthrite

Ostéomyélite


Ostéite



*Pourquoi l'arthrite septique ?*




Incidence IOA à *S. aureus*



Prévalence Arthrose


## *Histoire naturelle de l'arthrite septique ?*



# Un polymorphisme clinique pour une même bactérie : exemple du *S.aureus*...

« De la bombe nucléaire à la guerre de tranchée »


Phase pré-arthritique



| SOFA score                                                | 0                                         | 1                                             | 2                                             | 3                     | 4                 |
|-----------------------------------------------------------|-------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------|-------------------|
| <i>Respiratoire</i><br>PaO <sub>2</sub> /FiO <sub>2</sub> | 400<br><i>SaO<sub>2</sub> &gt; 95% AA</i> | 301-400<br><i>SaO<sub>2</sub> &gt; 91% AA</i> | 201-300<br><i>SaO<sub>2</sub> &lt; 90% AA</i> | 101-200               | < 100             |
| <i>Coagulation</i><br>Plaquettes                          | > 150                                     | 101-150                                       | 51-100                                        | 21-50                 | < 20              |
| <i>Hépatique</i><br>Bilirubine                            | < 20                                      | 20-32                                         | 33-101                                        | 102-204               | > 204             |
| <i>Cardiovasculaire</i><br>PAM                            | > 70 mmHg                                 | < 70 mmHg                                     | Dopamine<br>< 5                               | Dopamine<br>5-15      | Dopamine<br>> 15  |
| <i>Neurologique</i><br>Glasgow                            | 15                                        | 13-14                                         | 10-12                                         | 6-9                   | < 6               |
| <i>Rénale</i><br>Créatinine<br>Diurèse                    | < 110                                     | 110-170                                       | 171-299                                       | 300-440<br>< 500 mL/j | 440<br>< 200 mL/j |

SOFA 2 fébrile  
= Sepsis

Figure. Operationalization of Clinical Criteria Identifying Patients With Sepsis and Septic Shock



#### Quick-SOFA

- FR > 22/min
- Troubles de la vigilance
- PAS < 100 mmHg


#### SOFA > 2

- SaO<sub>2</sub> < 90% AA
- Glasgow < 12
- PAM < 70 mmHg malgré remplissage
- BT > 33
- Plq < 100
- Créat > 170




Lactates > 2 mmol/L

*Singer M. JAMA 2016;315:801-10.*

Phase pré-arthritique



## Phase pré-arthritique



PAMPs => TLR 2 et 6

$IL-1\beta$  => Source de production de métalloprotéases (MMP)  
action catabolique chondrocytaire

$TNF-\alpha$  => Action ostéoclaste par production RANK-Ligand

$IL-6$  => Activation complément/Opsonisation

$IL-12 / INF-\gamma$  => Activité Phagocytaire

Mécanisme de résistance aux peptides antimicrobiens de défense de l'hôte

- Expression gène *dltA-D*

*Catalyse l'introduction de la D-alanine dans les acides teichoïques de la paroi cellulaire,*

- Expression gène *mprF*

*Modification du phosphatidylglycérol membranaire par la L-lysine,*

- Production de Staphylokinase ou Aureolysin



Capacité de lier les défensines humaines, neutralisant ainsi leurs propriétés bactériolytiques

**Monoarthrite aiguë ± fébrile**

*Phase congestive = Phase diagnostique !*

Phase pré-arthritique

Phase congestive



- Ponction articulaire (culture positive > 80% des cas)
- Hémoculture (positive 30-50% des cas)

*Si négatifs que faire ?*

Arthrite septique à culture négative (notamment antibiothérapie préalable)

ou

autre diagnostic d'arthrite aiguë

=

Intérêt biomarqueur

< J0

J5

J15

|                                                                              |                                                                                                           |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Fort Inoculum bactérien<br>Pus (acide)                                       | <b>Drainage</b><br><b>Antibiothérapie</b><br><b>bactéricide sans risque de</b><br><b>mutant résistant</b> |
| Synoviale hypervascularisée<br>Spongieux hypervascularisé<br>Edème cartilage | Antibiothérapie actif en<br>milieu acide<br>Diffusion osseuse moyenne                                     |
| Drainage<br>B-lactamine<br><i>Glycopeptide/Lipopeptide</i>                   |                                                                                                           |

# Quel Biomarqueur sanguin ?

## CRP... ce n'est pas un marqueur d'infection !

CRP > 50 mg/L (Se 100 %, Sp 40 %, LR - < 0,1)

Shaikh MM. *Rheumatology (Oxford)*. 2015;54:231-40.

### Cohorte SYNOLACTATE


(253 arthrites < 30 jours) (10 % arthrites septique, 45 % arthrite métaboliques, 45 % arthrite aiguë associée RIC)

AUC 0.743

CRP 188.3 mg/L [88.8-288.6] vs 76.7 mg/L [29.8-132.5],  $p < 0.001$

CRP > 50 mg/L Se 88%, Sp 38,7%, LR+ 1.44, LR- 0,31

Berthoud O. *Joint Bone Spine*. Under Review.



# Quel Biomarqueur sanguin ?

## Procalcitonine (PCT)... n'a de valeur que si positive !



10 études (9 adultes + 1 enfant)

PCT > 0.5 ng/mL


AUC 0.82 (95% CI, 0.78-0.85)

Se 0.54 (95% CI, 0.41-0.66)

Sp 0.95 (95% CI, 0.87-0.98)

LR+ 10.97 (95% CI, 4.65-25.9)

LR- 0.49 (95% CI, 0.38-0.62)



Zhao J. Am J Emerg Med. 2017;35(8):1166-71.

# Quel Biomarqueur synovial ?

## Cytologie synoviale...

*plus le liquide est cellulaire, plus il est à risque septique !*

**THE RATIONAL**  
CLINICAL EXAMINATION

**CLINICIAN'S CORNER**

### Does This Adult Patient Have Septic Arthritis?

Mary E. Margaretten, MD  
Jeffrey Kohless, MD, MPH  
Dan Moore, PhD  
Stephen Best, MD

**CLINICAL SCENARIO**  
**Case 1**  
A 48-year-old woman with a history of rheumatoid arthritis who has been treated with long-term, low-dose prednisone presents to the emergency department with a 2-day history of a red, swollen left knee that is painful to touch. She reports no prior knee swelling and no recent trauma or knee surgery. (Legal drug use, rash, weight, or risky sexual behavior. On examination, she is afebrile and has a left knee effusion. Her peripheral white blood cell (WBC) count is 11 000/ $\mu$ L, and her erythrocyte sedimentation rate (ESR) is 55 mm/h. An arthrocentesis is performed and initial laboratory test results show a negative Gram stain, a synovial fluid WBC count of 46 000/ $\mu$ L, and the fluid culture is pending. What is the likelihood of septic arthritis in this patient?)

**Case 2**  
An 81-year-old man with diet-controlled diabetes mellitus and hypertension presents to the general medicine clinic with a painful left ankle. He reports difficulty walking for the past 2 days and his left ankle is exquisitely tender to touch. When he had pain in his ankle previously, another physician

**Context** In patients who present with an acutely painful and swollen joint, prompt identification and treatment of septic arthritis can substantially reduce morbidity and mortality.

**Objective** To review the accuracy and precision of the clinical evaluation for the diagnosis of nongonococcal bacterial arthritis.

**Data Sources** Structured PubMed and EMBASE searches (1966 through January 2007), limited to human, English-language articles and using the following Medical Subject Headings terms: arthritis, infectious, physical examination, medical history taking, diagnostic tests, and sensitivity and specificity.

**Study Selection** Studies were included if they contained original data on the accuracy or precision of historical items, physical examination, serum, or synovial fluid laboratory data for diagnosing septic arthritis.

**Data Extraction** Three authors independently abstracted data from the included studies.

**Data Synthesis** Fourteen studies involving 6242 patients, of whom 653 met the gold standard for the diagnosis of septic arthritis, satisfied all inclusion criteria. Two studies examined risk factors and found that age, diabetes mellitus, rheumatoid arthritis, joint surgery, hip or knee prosthesis, skin infection, and human immunodeficiency virus type 1 infection significantly increase the probability of septic arthritis. Joint pain (sensitivity, 89%; 95% confidence interval [CI], 78%-96%), a history of joint swelling (sensitivity, 78%; 95% CI, 71%-85%), and fever (sensitivity, 57%; 95% CI, 52%-62%) are the only findings that occur in more than 50% of patients. Sweats (sensitivity, 27%; 95% CI, 20%-34%) and rigors (sensitivity, 19%; 95% CI, 15%-24%) are less common findings in septic arthritis. Of all laboratory findings readily available to the clinician, the 2 most powerful were the synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells from arthrocentesis. The summary likelihood ratio (LR) increased as the synovial fluid WBC count increased (for counts <25 000/ $\mu$ L, LR, 0.32; 95% CI, 0.23-0.43; for counts >25 000/ $\mu$ L, LR, 2.9; 95% CI, 2.5-3.4; for counts >50 000/ $\mu$ L, LR, 7.7; 95% CI, 5.7-11.0; and for counts >100 000/ $\mu$ L, LR, 28.0; 95% CI, 12.0-66.0). On the same synovial fluid sample, a polymorphonuclear cell count of at least 90% suggests septic arthritis with an LR of 3.4 (95% CI, 2.8-4.0), while a polymorphonuclear cell count of less than 90% lowers the likelihood (LR, 0.34; 95% CI, 0.25-0.47).

**Conclusions** Clinical findings identify patients with peripheral, monoarticular arthritis who might have septic arthritis. However, the synovial WBC and percentage of polymorphonuclear cells from arthrocentesis are required to assess the likelihood of septic arthritis before the Gram stain and culture test results are known.

JAMA. 2007;297:1478-1488. www.jama.com

**Author Affiliations:** Division of Rheumatology (Dr Margaretten), Kern Program, Department of Statistics, University of California, San Francisco (Dr Kohless), and Department of Medicine, San Francisco Veterans Affairs Medical Center (Dr Kohless and Dr Best), and Department of Epidemiology and Biostatistics, University of California, San Francisco (Dr Moore).  
Corresponding Author: Mary E. Margaretten, MD, for JAMA.

**See also Patient Page.**  
**CME available online at**  
[www.jama.com](http://www.jama.com)

1478 JAMA, April 4, 2007—Vol 297, No. 13 (Reprinted) ©2007 American Medical Association. All rights reserved.

Pool 5 études de cohorte entre 1979 et 1998  
6242 arthrites dont 653 arthrites septiques (10,5 %)


Eléments nucléés liquide synovial

> 100000/mm<sup>3</sup> LR+ 28.0 (95% CI, 12.0-66)

> 50000/mm<sup>3</sup> LR+ 7,7 (95% CI, 5.7-11.0)

> 25000/mm<sup>3</sup> LR+ 2,9 (95% CI, 2,5-3,4)


LR- 0.32 (95% CI, 0.23-0.43)



Margaretten ME. JAMA. 2007;297:1478-88.

# Quel Biomarqueur synovial ?

... surtout s'il n'y a pas de cristaux !




**Table 2**

Performance of cytological markers alone or combined with microcrystal detection for diagnosing septic arthritis.

|                                                | Se (%) | Sp (%) | LR+   | LR-  |
|------------------------------------------------|--------|--------|-------|------|
| <b>Leukocyte count (/mm<sup>3</sup>)</b>       |        |        |       |      |
| > 50,000                                       | 53.60  | 91.70  | 5.76  | -    |
| > 70,000                                       | 39.30  | 95.60  | 8.93  | -    |
| < 20,000                                       | 92.30  | 70.60  | -     | 0.11 |
| <b>Percentage of neutrophils</b>               |        |        |       |      |
| > 90                                           | 71.40  | 79.70  | 3.52  | -    |
| > 95                                           | 50.00  | 89.00  | 4.55  | -    |
| < 80                                           | 96.20  | 56.90  | -     | 0.07 |
| <b>Neutrophil count (/mm<sup>3</sup>)</b>      |        |        |       |      |
| > 50,000                                       | 50.00  | 94.40  | 8.93  | -    |
| < 15,000                                       | 92.30  | 77.00  | -     | 0.1  |
| <b>Combinations of criteria</b>                |        |        |       |      |
| > 50,000/mm <sup>3</sup> leukocytes and no Cry | 53.60  | 95.10  | 10.94 | -    |
| > 90% Nph and no Cry                           | 67.90  | 92.80  | 8.28  | -    |
| > 95% Nph and no Cry                           | 50.00  | 95.60  | 11.36 | -    |
| > 50,000/mm <sup>3</sup> Nph and no Cry        | 35.70  | 96.70  | 10.82 | -    |

Se: sensitivity; Sp: specificity; LR+: positive likelihood ratio; LR-: negative likelihood ratio; Nph: neutrophils; Cry: microcrystals.

**Nomogramme d'interprétation  
Test Diagnostique**




Ferreyra M. Joint Bone Spine. 2017;84(:65-70.

## Quel Biomarqueur synovial ?

### PCT synoviale ? ... Match nul !

|  |                                                                                                                                                                                                                                                                                                                       |
|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | <p>Pas de différence significative entre arthrite septique 0,22 ng/mL (&lt;0,008-1,31) (n=11) et arthrite métabolique 0,09 ng/mL (&lt;0,08-0,88) (n=13).</p> <p><i>Martinot M. Clin Exp Rheumatol. 2005;23(3):303-10.</i></p>                                                                                         |
|  | <p>Pas de différence significative entre arthrites septiques (n=8), arthrite rhumatoïde (n=18) et arthrose (n=12)</p> <p><i>Streit G. Joint Bone Spine. 2008;75(2):238-9.</i></p>                                                                                                                                     |
|  | <p>AUC à 0.824    taux <math>\geq</math> 4,5 ng/mL,    LR+ 9,0<br/>                             taux &lt; 0,5 ng/mL,    LR+ 2.2    et    LR- 0.21<br/>           NB: groupe septique (n=26) n'était pas homogène (8 infections sur prothèse et 18 AS natives)</p> <p><i>Saeed K. Infection. 2013;41(4):845-9.</i></p> |
|  | <p>AUC à 0,951    taux <math>\geq</math> 2 ng/mL,    LR+ 17,1<br/>                             taux &lt; 0,5 ng/mL    LR+ 14.5    et    LR- 0.14</p> <p><i>Wang C. Exp Ther Med. 2014;8(4):1075-80.</i></p>                                                                                                           |



## Quel Biomarqueur synovial ?

### Lactate et Glucose... Pas parfait, mais intéressent !

Lactates AUC 0,864<sup>1</sup> et 0,901<sup>2</sup> Sp > 95% pour Seuil  $\geq$  10 mmol/L

Glucose AUC 0,701<sup>1</sup> et 0,960<sup>3</sup> Sp > 90 % pour Seuil < 1.8 mmol/L

En revanche, il n'y a pas de seuil permettant d'exclure une arthrite septique pour le lactate et le glucose.

<sup>1</sup>Lenski M. *Acta Orthop Belg.* 2014;80:18-25.

<sup>2</sup>Lenski M. *Clin Biochem.* 2014;47:49-55.

<sup>3</sup>Omar M. *J Bone Joint Surg Am.* 2014;96:2032-7.

#### Cohorte SYNOLACTATE

(253 arthrites < 30 jours) (10 % arthrites septique, 45 % arthrite métaboliques, 45 % arthrite aigue associée RIC)

Lactate AUC 0,795, Seuil  $\geq$  10 mmol/L LR+ 41.6

Glucose AUC 0.833, Seuil < 1,8 mmol/L LR+ 15.6

Ratio Lactate/Glucose, Seuil > 5 LR+ 27.0

Berthoud O. *Joint Bone Spine.* Under Review.





L. P. Guggenbuhlus

D. P. Guggenbuhlus

## Quel Biomarqueur synovial ?

D-Lactate est l'énantiomère du L-Lactate.  
Synthèse uniquement par procaryotes




Cohorte 57 arthrites (10 arthrites septiques)

Seuil > 0,05 mmol/L,


Se = 90%, Sp = 87 %

LR+ = 11.5

LR- = 0.14



Marcos MA. Eur J Clin Microbiol Infect Dis. 1991;10:966-9.



# Calprotectine ?


AUC 0,720,  
Seuil de 854 µg/mL  
Se 73%, Sp 67 %  
LR+2,2

Couderc M. Joint Bone Spine. 2019;86:261-2.

AUC 0.877,  
Se 76%, Sp 94%  
LR+= 12.2 seuil > 150 mg/L  
LR- = 0.09 seuil < 52 mg/L

Baillet A. Rheumatology. 2019;58:1644-8.

## Quel Biomarqueur synovial ?



ORIGINAL ARTICLE

# MALDI-TOF MS performance compared to direct examination, culture, and 16S rDNA PCR for the rapid diagnosis of bone and joint infections

E. Lallemand<sup>1</sup>, G. Coiffier<sup>1,2,3,4</sup>, C. Arvieux<sup>1,2</sup>, E. Brillet<sup>1,4</sup>, P. Guggenbuhl<sup>1,2,3,4</sup>, A. Jolivet-Goggeon<sup>1,2,3,4</sup>

Received: 3 December 2015 / Accepted: 12 February 2016 / Published online: 4 March 2016  
© Springer-Verlag Berlin Heidelberg 2016

**Abstract** The rapid identification of bacterial species involved in bone and joint infections (BJI) is an important element to optimize the diagnosis and care of patients. The aim of this study was to evaluate the usefulness of matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS) for the rapid diagnosis of bone infections, directly on synovial fluid (SF) or on crushed osteoarticular samples (CS). From January to October 2013, we prospectively analyzed 111 osteoarticular samples (bone and joint samples, BJS) from 78 patients in care at the University Hospital of Rennes, France. The diagnosis procedure leading to the sample collection was linked to a suspicion of infection, inflammatory disease, arthritis, or for any bone or joint abnormality. Standard bacteriological diagnosis and molecular biology analysis (16S rDNA polymerase chain reaction (PCR) and

sequencing) were conducted. In addition, analysis by MALDI-TOF MS was performed directly on the osteoarticular samples, as soon as the amount allowed. Culture, which remains the gold standard for the diagnosis of BJI, has the highest sensitivity (85.9 %) and remains necessary to test antimicrobial susceptibility. The 16S rDNA PCR results were positive in the group with positive BJI (28.6 %) and negative in the group without infection. Direct examination remains insensitive (31.7 %) but more effective than MALDI-TOF MS directly on the sample (6.3 %). The specificity was 100 % in all cases, except for culture (74.3 %). Bacterial culture remains the gold standard, especially enrichment in blood bottles. Direct analysis of bone samples with MALDI-TOF MS is not useful, possibly due to the low intensity of BSI.

## Introduction

Bone infections are composed of several pathologies, like septic arthritis, osteomyelitis, spondylodiscitis, diabetic foot, or prosthetic infection, that can gradually evolve into complex bone and joint infections (BJI), with important mortality and morbidity [1–3]. The diagnosis of bone infections based on clinical, bacteriological, radiological, and histological arguments and its interpretation is facilitated by the publication of guidelines, such as the recommendations of the Société de Pathologie Infectieuse de Langue Française (SPILF) [4] or the Infectious Diseases Society of America (IDSA) [5].

The role of the bacteriology laboratory in the management of samples from patients with BJI is important. For surgical specimens, it is recommended to collect five samples (less than five causes difficulties of interpretation and more than five increases the risk of contamination without improving the sensitivity) [4, 6]. The probability of infection increases

✉ A. Jolivet-Goggeon  
a.jolivet-goggeon@univ-rennes.fr

<sup>1</sup> Pôle Rhumatisme, Rennes University Hospital, rue Henri Le Goffic, 35043 Rennes, France

<sup>2</sup> INSERM U1085, Rennes, France

<sup>3</sup> Centre de Référence pour les Infections Ostéo-articulaires, Compagnie du Grand Ouest (CROCO), Rennes, France

<sup>4</sup> Service de Rhumatologie, Rennes University Hospital, rue Henri Le Goffic, 35043 Rennes, France

<sup>5</sup> Service de Maladies Infectieuses, Rennes University Hospital, rue Henri Le Goffic, 35043 Rennes, France

<sup>6</sup> Infectiologie Ostéo-articulaires, Rennes University Hospital, rue Henri Le Goffic, 35043 Rennes, France

<sup>7</sup> Université de Rennes 1, 35043 Rennes, France

<sup>8</sup> Equipe de Microbiologie, EA 1254, Université de Rennes 1, 2, avenue du Professeur Léné Bérard, 35043 Rennes, France



Clinical Rheumatology  
https://doi.org/10.1007/s10067-019-04462-7

ORIGINAL ARTICLE

# Broad-range 16S rDNA PCR in synovial fluid does not improve the diagnostic performance of septic arthritis in native joints in adults: cross-sectional single-center study in 95 patients

G. Coiffier<sup>1,2</sup>, C. David<sup>1</sup>, P. Gauthier<sup>1</sup>, H. Le Bars<sup>1</sup>, P. Guggenbuhl<sup>1,2</sup>, A. Jolivet-Goggeon<sup>1,2</sup>, J.-D. Albert<sup>1,2</sup>

Received: 12 September 2018 / Revised: 12 February 2019 / Accepted: 24 February 2019  
© International League of Associations for Rheumatology (ILAR) 2019

## Abstract

**Objective** To evaluate the diagnostic performance of bacterial identification by broad-range polymerase chain reaction (PCR) of ribosomal DNA (rDNA) 16S (16S rDNA PCR) for the diagnosis of septic arthritis on native joints.

**Methods** Patients with acute mono or oligoarthritis who underwent synovial fluid puncture and prospective follow-up allowing definitive diagnosis (septic arthritis, crystal related disease, chronic inflammatory arthritis, undifferentiated arthritis) were recruited in this single-center study. Systematic analysis of synovial fluid included leukocytes count, search for urate and pyrophosphate crystals with polarized light microscopy, direct bacteriological examination (gram staining), bacteriological culture, and 16S rDNA PCR.

**Results** Ninety-five patients were included, 34 of which (35.8 %) had septic arthritis. Nineteen (20.0 %) patients had received prophylactic antibiotic therapy prior to joint puncture. Gram + cocci infection accounted for 79.4 % of septic arthritis, of which nearly half (47.1 %) was caused by *Staphylococcus aureus*. Eight (23.5 %) septic arthritis patients had a 16S rDNA PCR positive in the synovial fluid with an AUC of 0.618 (95 % CI 0.493–0.742), a sensitivity of 0.24 (95 % CI 0.12–0.40), and a specificity of 1.00 (95 % CI 0.94–1.00). The diagnostic performance of 16S rDNA PCR was lower than that of direct examination (AUC: at 0.601, CI 95%, 0.570–0.632), blood culture (AUC at 0.727, CI 95%, 0.610–0.844), and culture (0.925, CI 95%, 0.856–0.994) for the diagnosis of septic arthritis. There was no difference in the positivity of 16S rDNA PCR according to previous exposure to antibiotics.

**Conclusion** 16S rDNA PCR in the synovial fluid does not improve the diagnostic performance of septic arthritis on native adult joints, particularly for Gram-positive cocci infections.

**Keywords** 16S rDNA PCR · Septic arthritis · Synovial fluid

## Introduction

Septic arthritis is a diagnostic and therapeutic medical emergency due to excess mortality (2 % at 1 month, approximately

10 % at 1 year) and the frequency of joint functional sequelae (approximately 50 %), requiring antibiotic therapy adapted to the microorganisms involved [1–3]. The incidence of septic arthritis in native joints is increasing, particularly in subjects over 75 years of age [4], a population also exposed to crystal related arthritis, its main differential diagnosis [5].

Microbiological culture of joint fluid is considered the reference technique for bacterial identification. However, the sensitivity of this method varies from 67 to 87 % for bacterial identification in septic arthritis cases [6–8]. The failure of conventional microbiological diagnosis techniques could be explained by the initiation of prior antibiotic therapy and the presence of slow-growing or non-cultivable bacteria on usual media [9].

Since the late 2000s, numerous publications [10–15] have reported the use of a new molecular biology technique, the broad-range polymerase chain reaction (PCR) targeting genes

✉ J.-D. Albert

jean-david.albert@univ-rennes.fr

<sup>1</sup> Service de Rhumatologie, CHU, Hôpital Sud, 16 boulevard du Baguier, 35203 Rennes, France

<sup>2</sup> Institut NORDICAN, INSERM U 1241, INRA U 1241, 35000 Rennes, France

<sup>3</sup> EA 1254 Microbiologie Université de Rennes 1, Laboratoire Bactériologie CHU, Fochelation, 35000 Rennes, France

Published online: 08 March 2019



Quel Biomarqueur synovial ?

DNAr 16S, PCR universelle... mais souvent absente !

|                        | AUC                 | Sensitivity      | Specificity      | LR+  | LR–  |
|------------------------|---------------------|------------------|------------------|------|------|
| Direct examination     | 0.691 (0.570–0.812) | 0.38 (0.24–0.55) | 1.00 (0.94–1.00) | +∞   | 0.62 |
| Synovial fluid culture | 0.925 (0.856–0.994) | 0.88 (0.73–0.95) | 0.97 (0.89–0.99) | 26.9 | 0.12 |
| 16S rDNA PCR           | 0.618 (0.493–0.742) | 0.24 (0.12–0.40) | 1.00 (0.94–1.00) | +∞   | 0.77 |
| Blood culture          | 0.727 (0.610–0.844) | 0.47 (0.31–0.63) | 0.98 (0.91–0.99) | 28.7 | 0.54 |

Lallemand E. Eur J Clin Microbiol Infect Dis. 2016;35:857–66.

|                   | Culture | Direct examination (Gram staining) | 16S rDNA PCR on sample | MALDI-TOF MS on sample |
|-------------------|---------|------------------------------------|------------------------|------------------------|
| Sensitivity       | 85.9    | 31.3                               | 29.6                   | 7.4                    |
| Specificity       | 74.5    | 100                                | 100                    | 100                    |
| PPV               | 82.1    | 100                                | 100                    | 100                    |
| NPV               | 79.5    | 51.6                               | 67.2                   | 60.9                   |
| AUC               | 0.849   | 0.593                              | 0.648                  | 0.532                  |
| Number of samples | 111     | 111                                | 66                     | 66                     |



Coiffier G. Clin Rheumatol. 2019;38:1985–92.



## Drainage au cours de l'arthrite septique ?

Phase pré-arthritique

Phase congestive




J5

J15

|                                                                               |                                                                                                           |
|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Fort Inoculum bactérien<br>Pus (acide)                                        | <b>Drainage</b><br><b>Antibiothérapie</b><br><b>bactéricide sans risque de</b><br><b>mutant résistant</b> |
| Synoviale hypervascularisée<br>Spongieux hypervascularisé<br>Cedème cartilage | Antibiothérapie actif en<br>milieu acide<br>Diffusion osseuse moyenne                                     |
| Drainage<br>B-lactamine<br><i>Glycopeptide/Lipopeptide</i>                    |                                                                                                           |

Chirurgie ou Ponction itérative ?



\* Comorbidités = PR (15.8%), Diabète (9.5%), Immunosuppresseur (7.1%), Alcool/Cirrhose (6.25%), IRC (3%)

Broy SB. Clin Rheum Dis 1986;12:501-22.

# Chirurgie au cours de l'arthrite septique : moins de sequelles ?



## Native septic arthritis is not an immediate surgical emergency<sup>†</sup>

Nicolas Lauper<sup>1,2</sup>, Marie Davat<sup>1,3</sup>, Ergys Gjika<sup>4,5</sup>, Camillo Müller<sup>4,5</sup>, Wilson Beliaeff<sup>1</sup>, Didier Tettex<sup>1,2</sup>, Benjamin A. Uipoly<sup>1,2</sup>, Didier Hannouche<sup>1</sup>, Ilker Uçkay<sup>1,2,6,7</sup>

<sup>1</sup>Orthopaedic Surgery Service, Geneva University Hospital;  
<sup>2</sup>Service of Infectious Diseases, Geneva University Hospital;  
<sup>3</sup>Joint Surgery Unit, Geneva University Hospital;  
<sup>4</sup>Infection Control Program, University of Geneva Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland;  
<sup>5</sup>Division of Medical Sciences, University of Oxford, UK

### ARTICLE INFO

Article history:  
Received 7 February 2018  
Available online 8 May 2018  
Keywords:  
Septic arthritis  
Emergency surgery  
Functional outcome  
Treatment

### SUMMARY

**Summary:** Acute native joint septic arthritis is generally considered a surgical emergency, requiring drainage within hours, including during night, weekend or holiday shifts. However, there are few data supporting the need for the drainage caused by the degree of sepsis.  
**Methods:** We performed a retrospective review of all adult patients seen in our medical center from 1997–2015 with culture-proven septic arthritis and noted the epidemiology of sepsis, and their possible association with a delay in surgical drainage.  
**Results:** Of 248 septic arthritis episodes, 46 (23%) involved nonweight-bearing hand and foot joints. Large joints involved included the knee (n=17), shoulder (48), hip (22), ankle (8), acromioclavicular (5), elbow (4), wrist (3), and sternoclavicular (1) regions. All patients underwent surgical drainage of the joint and received targeted systemic antibiotic therapy. Severity of sepsis occurred in 83 patients (49%); recurrences (n=15); secondary arthritis (10); persistent pain (3); Cellulitis/sepsis (10); embolism (9); amputation (8); infection (8); and Chronic Regional Pain Syndrome (2). By multivariate Cox regression analysis factors did not predict sepsis included: age, treatment with systemic corticosteroids, pre-existing clinical or radiological arthropathy, total duration of antibiotic therapy, type of joint, and number of surgical interventions. Similarly, there was no association of sepsis with the number of days of pre-hospitalization joint symptoms (azard ratio 1.0, 95% confidence interval 0.89–1.04) or hours spent in the emergency department (0.8–1.0, 95% confidence interval 0.69–1.04) or hours of presentation had similar functional outcomes as those with longer delay at 6–12 h, 12–24 h, or >24 h after presentation.  
**Conclusion:** Our data suggest that for native septic arthritis, in the absence of clinical sepsis immediate joint drainage does not appear to reduce the risk of sepsis compared with delayed drainage.  
© 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

### Introduction

Acute native joint septic arthritis is typically considered a medical emergency, requiring urgent surgical intervention to help reduce cartilage damage and to prevent good long-term joint

function.<sup>1–10</sup> Both surgeons and physicians are taught that they should ensure joint drainage is performed within hours after hospital admission, even in the absence of clinical evidence of sepsis or during night, weekend or holiday shifts. Emergency surgical treatment of patients with septic arthritis, independent of the time elapsed between the onset of symptoms and admission, may actually be detrimental, especially for elderly bedridden patients. Furthermore, mobilizing the specialist to properly drain a septic joint can be time-consuming and costly. Although this recommendation has been widely and repeatedly made in the surgical literature, there are few data supporting the need for urgent surgical drainage of a septic joint.<sup>1–4</sup>

In a previously published study of antibiotic treatment of septic arthritis,<sup>11</sup> we found that the incidence of long-term adverse sequelae of this infection was 20%. By regression analysis we found no

<sup>†</sup> The material presented in this paper has not been previously published, nor has it been submitted elsewhere for publication. The data presented are the work of all authors listed. None of the authors have any conflict of interest or financial interest in connection with this work. All authors have seen, approved, and consented to the manuscript. There was no funding for this study.  
Corresponding author at: Orthopaedic Surgery Service, Geneva University Hospitals, 4, rue Gabrielle Perregé-Gentil 1205 Geneva, Switzerland.  
E-mail address: nicolas.lauper@unige.ch (N. Lauper).  
† Equal contribution to this article.

## Factors associated with sequelae after native joint septic arthritis (Cox regression analysis).

| n = 204                                | Univariate analysis<br>Hazard ratio (95%<br>confidence interval) | Multivariate analysis<br>Hazard ratio (95%<br>confidence interval) |
|----------------------------------------|------------------------------------------------------------------|--------------------------------------------------------------------|
| Pre-hospital delay until-surgery       | 1.0 (1.0–1.0)                                                    | 1.0 (1.0–1.0)                                                      |
| - duration >7 days compared to ≤7 days | 1.0 (0.6–1.5)                                                    | -                                                                  |
| Delay admission to surgery             | 1.0 (0.9–1.1)                                                    | -                                                                  |
| > 3 days compared to ≤ 3 days          | 1.1 (0.7–1.8)                                                    | -                                                                  |
| Delay admission to surgery             | 1.0 (0.9–1.1)                                                    | 1.0 (0.9–1.2)                                                      |
| - ≤ 6 h                                | -                                                                | 0.9 (0.4–1.8)                                                      |
| - > 6 h to ≤ 12 h                      | -                                                                | 0.9 (0.4–2.1)                                                      |
| - > 12 h to ≤ 24 h                     | -                                                                | 0.8 (0.5–1.4)                                                      |

# Faut-il toujours initier une antibiothérapie IV ?

**X Non**

THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

## Oral versus Intravenous Antibiotics for Bone and Joint Infection

H.-K. Li, I. Bombach, R. Zambellas, A.S. Walker, M.A. McNally, B.L. Atkins, B.A. Lipky, H.C. Hughes, D. Bore, M. Kirmin, C. Scarborough, P.C. Matthews, A.J. Brent, J. Lomas, R. Gundie, M. Rogers, A. Taylor, B. Angus, I. Byren, A.R. Berendt, S. Warren, F.E. Fitzgerald, D.J.F. Mack, S. Hopkins, J. Folb, I.E. Reynolds, E. Mouny, J. Marshall, N. Jenkins, C.E. Moran, A.F. Woodhouse, S. Stafford, R.A. Seaton, C. Vallance, C.J. Hemslay, K. Bismuthsing, J.A.T. Sandoe, I. Aggarwal, S.C. Ellis, D.J. Bunn, R.K. Sutherland, G. Barlow, C. Cooper, C. Geue, N. McMeekin, A.H. Briggs, P. Sendi, E. Khatamzas, T. Wangrungsakul, T.H.N. Wong, L.K. Barrett, A. Alward, C.F. Ong, J. Bostock, J. Paul, C. Cooke, G.E. Thwaites, P. Bejon, and M. Scarborough, for the OVIVA Trial Collaborators\*

**ABSTRACT**

**BACKGROUND**  
The management of complex orthopedic infections usually includes a prolonged course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is noninferior to intravenous antibiotic therapy for this indication.


**METHODS**  
We enrolled adults who were being treated for bone or joint infection at 26 U.K. centers. Within 7 days after surgery (or, if the infection was being managed without surgery, within 7 days after the start of antibiotic treatment), participants were randomly assigned to receive either intravenous or oral antibiotics to complete the first 6 weeks of therapy. Follow-on oral antibiotics were permitted in both groups. The primary end point was definitive treatment failure within 1 year after randomization. In the analysis of the risk of the primary end point, the noninferiority margin was 75 percentage points.

**RESULTS**  
Among the 1054 participants (527 in each group), end-point data were available for 1015 (96.3%). Treatment failure occurred in 74 of 506 participants (14.6%) in the intravenous group and 67 of 509 participants (13.2%) in the oral group. Missing end-point data (39 participants, 3.7%) were imputed. The intention-to-treat analysis showed a difference in the risk of definitive treatment failure (oral group vs. intravenous group) of -1.4 percentage points (95% confidence interval [CI], -4.0 to 2.2; 95% CI, -5.6 to 2.9), indicating noninferiority. Complete-case, per-protocol, and sensitivity analyses supported this result. The between-group difference in the incidence of serious adverse events was not significant (146 of 527 participants [27.7%] in the intravenous group and 138 of 527 [26.2%] in the oral group;  $P=0.58$ ). Catheter complications, analyzed as a secondary end point, were more common in the intravenous group (0.4% vs. 1.0%).

**CONCLUSIONS**  
Oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first 6 weeks for complex orthopedic infection, as assessed by treatment failure at 1 year. (Funded by the National Institute for Health Research; OVIVA Current Controlled Trials number, 18RC19156987.)

N Engl J Med 2019;380:425-36.  
DOI: 10.1056/NEJMoa1710926  
Copyright © 2019 Massachusetts Medical Society.

425



Li HK. N Engl J Med. 2019;380:425-36.

# Faut-il toujours initier une antibiothérapie IV ?

Sauf que...


## Critères d'exclusion

- 1) Bactériémie à *Staphylococcus aureus*
- 2) Endocardite bactérienne,
- 3) Toute autre infection concomitante nécessitant une antibiothérapie intraveineuse prolongée (ex. infection médiastinale ou infection du SNC)
- 4) Une infection pour laquelle il n'y avait pas de choix d'antibiotiques (par exemple, lorsque les organismes étaient seulement sensibles aux antibiotiques IV).
- 5) Choc septique ou sepsis sévère
- 6) Preuves cliniques, histologiques ou microbiologiques de mycobactéries, champignons, étiologie parasitaire ou virale de l'infection




Li HK. N Engl J Med. 2019;380:425-36.

## *Pourquoi une antibiothérapie bactéricide ?*



*LaPlante KL. Antimicrob Agents Chemother. 2004;48(12):4665-72.*



< J0      J5      J15      J45

|                                                                               |                                                                                                           |                                                                                                                                        |                                                                                              |
|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Fort Inoculum bactérien<br>Pus (acide)                                        | <b>Drainage</b><br><b>Antibiothérapie</b><br><b>bactéricide sans risque de</b><br><b>mutant résistant</b> | Diminution inoculum<br>bactérien                                                                                                       | <b>Antibiothérapie à</b><br><b>bonne diffusion</b><br><b>tissulaire et</b><br><b>osseuse</b> |
| Synoviale hypervascularisée<br>Spongieux hypervascularisé<br>Cedème cartilage | Antibiothérapie actif en<br>milieu acide<br>Diffusion osseuse moyenne                                     | Synovite proliférative<br>Moindre vascularisation<br>Dissection sous-chondrale<br>Chondromalacie<br>Erosion osseuse<br>Biofilm dès J15 |                                                                                              |
| Drainage<br>B-lactamine<br><i>Glycopeptide/Lipopeptide</i>                    |                                                                                                           | Synovectomie<br>Relai vers Rifampicine et/ou FQ                                                                                        |                                                                                              |

# Evolution de la synovite infectieuse ?

**Table 3**

Changes in the ultrasound appearance of the synovial membrane over the 3-month follow-up.

|                                           | Baseline  | Day 4                         | Week 2                       | Month 3                            |
|-------------------------------------------|-----------|-------------------------------|------------------------------|------------------------------------|
| Assessable ultrasound scans               | 28/34     | 27/34                         | 31/34                        | 27/34                              |
| Synovitis                                 | 27 (96.4) | 26 (96.3)                     | 31 (100)                     | 21 (77.8)                          |
| Intraindividual change in thickness       |           | 17.3(−1 to +228) <sup>*</sup> | 20(−20 to +200) <sup>*</sup> | −31.5(−83.7 to +27.5) <sup>*</sup> |
| Number of assessable cases                |           | n = 22                        | n = 23                       | n = 22                             |
| Doppler                                   | 18 (64.3) | 18 (66.7)                     | 19 (61.3)                    | 7 (25.9) <sup>***</sup>            |
| Grade 1                                   | 6         | 6                             | 10                           | 3                                  |
| Grade 2                                   | 11        | 8                             | 7                            | 3                                  |
| Grade 3                                   | 1         | 4                             | 2                            | 1                                  |
| Intraindividual decrease in Doppler grade |           | 6 (26)                        | 9 (31)                       | 14 (56)                            |
| Number of assessable cases                |           | n = 23                        | n = 29                       | n = 25                             |

The data are n (%) for categorical data and median (interquartile range) for the intraindividual change in synovial membrane thickness in the assessable patients.

<sup>\*</sup> P < 0.02.

<sup>\*\*</sup> P < 0.05.

**Table 4**

Changes in the other ultrasound parameters over the 3-month follow-up.

|                                       | Baseline  | Day 4     | Week 2    | Month 3                 |
|---------------------------------------|-----------|-----------|-----------|-------------------------|
| Number of assessable ultrasound scans | 28/34     | 27/34     | 31/34     | 27/34                   |
| Joint effusion                        | 26 (92.8) | 24 (88.9) | 25 (80.6) | 15 (55.6) <sup>**</sup> |
| Joint cavity loculation               | 6 (21.4)  | 6 (22.2)  | 6 (19.4)  | 0                       |
| Erosions                              | 5 (17.9)  | 4 (14.8)  | 10 (32.3) | 14 (51.8)               |
| Cellulitis                            | 0         | 1 (3.7)   | 0         | 0                       |
| Muscle abscess                        | 3 (10.7)  | 2 (7.4)   | 5 (16)    | 1 (3.7)                 |

The data for categorical variables are n (%).

<sup>\*\*</sup> P < 0.05.



Gaigneux E. Joint Bone Spine. 2017;84:599-604.



# MRI findings for unilateral sternoclavicular arthritis: differentiation between infectious arthritis and spondyloarthritis

Byeong Seong Kang<sup>1</sup> · Hyun Seok Shim<sup>1</sup> · Woon Jung Kwon<sup>1</sup> · Soyeoun Lim<sup>1</sup> · Gyeong Min Park<sup>1</sup> · Tae Young Lee<sup>1</sup> · Minseo Bang<sup>1</sup>

Received: 13 April 2018 / Revised: 19 June 2018 / Accepted: 24 June 2018 / Published online: 5 July 2018  
© 2018

## Abstract

**Objectives** To analyze and identify magnetic resonance imaging (MRI) and clinical findings for the differentiation between infectious arthritis and spondyloarthritis in patients with unilateral sternoclavicular arthritis.

**Materials and methods** We retrospectively collected and evaluated the magnetic resonance (MR) images of 21 patients diagnosed with unilateral sternoclavicular arthritis, including 12 with infection and nine with spondyloarthritis, between 2004 and 2017. Capsular distension, extracapsular fluid collection, peritarticular muscle edema, the prevalence and distribution of bone marrow edema, and the prevalence and size of bone erosions were assessed on the MR images. Clinical data were also reviewed.

**Results** Capsular distension was more prominent in patients with infectious arthritis than those with spondyloarthritis ( $p = 0.002$ ); extracapsular fluid collection and peritarticular muscle edema were also more common in infectious arthritis than spondyloarthritis ( $p < 0.001$ , respectively); moreover, bone erosions were larger in infectious arthritis than spondyloarthritis ( $p = 0.023$ ). Other findings significantly associated with infectious arthritis included advanced age ( $p = 0.007$ ), an elevated C-reactive protein (CRP) level ( $p = 0.001$ ), and erythrocyte sedimentation rate (ESR) ( $p < 0.001$ ). The prevalence and distribution of bone marrow edema and the prevalence of bone erosions on MRI, the white blood cell count, and sex showed no significant differences between the two groups.

**Conclusions** Capsular distension, extracapsular fluid collection, peritarticular muscle edema, and the size of bone erosions on MRI, as well as the age, CRP level, and ESR of patients, could be helpful for differentiating infectious arthritis from spondyloarthritis involving the sternoclavicular joint.

**Keywords** Arthritis · Infectious · Magnetic resonance imaging · Spondyloarthritis · Sternoclavicular joint

## Introduction

The sternoclavicular joint is the diarthrodial articulation between the axial and appendicular skeletons. It is susceptible to the same disease processes that occur in joints, including degenerative arthritis, infection, and subluxation [1]. Moreover, it is a commonly involved site in patients with spondyloarthritis [2–5]. Although symmetrical involvement is seen in the majority of patients with spondyloarthritis, uni-

lateral involvement of the sternoclavicular joint has been noted in the early stages of ankylosing spondylitis, psoriatic arthritis, and reactive arthritis [2].

Differentiation between infectious arthritis and spondyloarthritis involving the sternoclavicular joint is very important for the selection of appropriate therapeutic approaches. Prompt diagnosis and treatment are crucial because untreated infection may lead to life-threatening consequences such as mediastinitis or empyema [1, 6, 7].


To our knowledge, no studies have attempted to differentiate between infectious arthritis and spondyloarthritis involving the sternoclavicular joint using magnetic resonance imaging (MRI). Accordingly, we designed the present study to analyze and identify MRI and clinical findings for the differentiation between infectious arthritis and spondyloarthritis in patients with unilateral sternoclavicular arthritis.

✉ Byeong Seong Kang  
kbsr1234@chol.com

<sup>1</sup> Department of Radiology, University of Ulsan College of Medicine, Ulsan University Hospital, 877 Bangsongno, Busanjin-gu, Dong-gu, Ulsan 44033, South Korea



# Histologie de la synovite infectieuse ?



OA: Osteoarthritis, SA: Septic Arthritis, CA: Crystal Arthropathy

Coiffier G. Clin Rheumatol. 2018;37:2241-9.

Clinical Rheumatology (2018) 37:2241–2249  
https://doi.org/10.1007/s10067-018-4160-9

ORIGINAL ARTICLE



**Ultrasound-guided synovial biopsy improves diagnosis of septic arthritis in acute arthritis without enough analyzable synovial fluid: a retrospective analysis of 176 arthritis from a French rheumatology department**

Guillaume Coiffier<sup>1,2</sup> · Marine Ferreyra<sup>3</sup> · Jean-David Albert<sup>1,2</sup> · Nathalie Stock<sup>4</sup> · Anne Jolivet-Gougeon<sup>1,2</sup> · Aloïse Pordolige<sup>5</sup> · Pascal Guggenbuhl<sup>1,2</sup>

Received: 17 March 2018 / Revised: 20 May 2018 / Accepted: 24 May 2018 / Published online: 14 June 2018  
© International League of Associations for Rheumatology (ILAR) 2018

**Abstract**  
To assess the diagnostic value of ultrasound-guided (US-guided) synovial biopsy in routine clinical practice in cases of acute and chronic arthritis. A retrospective, single-center study of US-guided synovial biopsies between 2003 and 2013. The clinical, laboratory, radiographic, synovial fluid, and histological and bacteriological results of synovial biopsies were analyzed. Arthritis was classified according to disease duration < 6 weeks (AA) or ≥ 6 weeks (CA). Synovial biopsy success rate was defined by the rate of capsular and/or synovial tissue analyzed. The diagnostic efficiency was defined by synovial biopsy success rate multiplied by the clinical utility (validation of a diagnostic hypothesis leading to a specific therapy). One hundred seventy-six US-guided synovial biopsies (51 AA and 125 CA) were analyzed. Synovial biopsy success rate was 82.4%. The diagnostic efficiency was 19.9%. Among the acute arthritis cases, 11 were septic. Only three patients had a positive biopsy culture while the synovial fluid puncture was of insufficient quantity to allow bacteriological analysis. The perivascular infiltration of neutrophils (PMN) had a sensitivity of 81.8%, a specificity of 84.2%, and a positive likelihood ratio of 5.2 for the septic arthritis diagnosis. Among the chronic arthritis cases, no case of pyogenic arthritis was found. No histological lesions, examined separately, were specific to a type of chronic inflammatory joint disease. US-guided synovial biopsies remain relevant for the diagnosis of septic arthritis, in cases of acute arthritis when joint aspiration is not possible.

**Keywords** Arthritis · Diagnosis · Synovial biopsy · Ultrasound

**Highlights**  
• A total of 82.4% of US-guided synovial biopsies were able to analyze capsular and/or synovial tissue.  
• US-guided synovial biopsies seem to be useful for the diagnosis of septic arthritis when joint aspiration is not possible or in the absence of synovial fluid.  
• The perivascular infiltration of neutrophils had a positive likelihood ratio of 5.2 for the pyogenic septic arthritis.

**Electronic supplementary material** The online version of this article (https://doi.org/10.1007/s10067-018-4160-9) contains supplementary material, which is available to authorized users.

✉ Guillaume Coiffier  
guillaume.coiffier@univ-rennes.fr

<sup>1</sup> Rheumatology Department, Rennes University Hospital - Hôpital Sud, 16 boulevard de Bulgarie, BP90047, 35205 Rennes Cedex 2, France


<sup>2</sup> INSERM 1241, Rennes 1 University, Rennes, France

<sup>3</sup> Rheumatology Department, Vannes Hospital, Hôpital Chébert, 20 Boulevard Général Marceau-Guillevin, 56000 Vannes, France

<sup>4</sup> Pathology Department, Rennes University Hospital - Pontchaillou, 2 Rue Henri Le Gallou, 35000 Rennes, France


<sup>5</sup> Bacteriology Laboratory, Rennes University Hospital - Pontchaillou, 2 Rue Henri Le Gallou, 35000 Rennes, France






|                                                                              |                                                                                                           |                                                                                                                                        |                                                                                              |                                                                                                                                 |                                                                                                                                                                          |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fort Inoculum bactérien<br>Pus (acide)                                       | <b>Drainage</b><br><b>Antibiothérapie</b><br><b>bactéricide sans risque de</b><br><b>mutant résistant</b> | Diminution inoculum<br>bactérien                                                                                                       | <b>Antibiothérapie à</b><br><b>bonne diffusion</b><br><b>tissulaire et</b><br><b>osseuse</b> | Destruction ostéo-articulaire<br>Sequestre ostéo-chondral<br>Small Colony Variants<br>Internalisation Ostéoblastique<br>Biofilm | <b>Antibiothérapie à</b><br><b>bonne diffusion</b><br><b>tissulaire et osseuse</b><br><b>Activité intracellulaire</b><br><b>Activité en phase</b><br><b>stationnaire</b> |
| Synoviale hypervascularisée<br>Spongieux hypervascularisé<br>Œdème cartilage | Antibiothérapie actif en<br>milieu acide<br>Diffusion osseuse moyenne                                     | Synovite proliférative<br>Moindre vascularisation<br>Dissection sous-chondrale<br>Chondromalacie<br>Erosion osseuse<br>Biofilm dès J15 |                                                                                              |                                                                                                                                 |                                                                                                                                                                          |
| Drainage<br>B-lactamine<br><i>Glycopeptide/Lipopeptide</i>                   |                                                                                                           | Synovectomie<br>Relai vers Rifampicine et/ou FQ                                                                                        |                                                                                              | Arthroplastie<br>Relai vers <b>Rifampicine</b> (Gram +)<br>et/ou FQ (avec RIF ou Gram -)                                        |                                                                                                                                                                          |

## Réduction Inoculum Intraostéoblastique



## Nombre de SCV



Dimanche 8 Décembre 2019

**15:55 Actualisation des recommandations françaises pour le diagnostic et la prise en charge des arthrites septiques sur articulation native**

M. Couderc (Clermont-Ferrand), G. Bart (Nantes), / . pour le Groupe SFR sur les infections ostéoarticulaires



| <i>Espèce bactérienne</i>                | Antibiotique IV en première intention                                      | Antibiotique PO en relai                                                                                                                               | Antibiotique en cas de contre-indication                                                                                                     |
|------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| SAMS                                     | cloxa- ou oxacilline ou cefazoline                                         | Rifampicine + Ofloxacine ou Levofloxacine<br>Clindamycine + Ofloxacine ou Levofloxacine                                                                | Avis infectiologique<br>Choix parmi<br><i>Daptomycine</i><br><i>Rifampicine + autres (Clindamycine, cotrimoxazole, cyclines, linézolide)</i> |
| SARM                                     | Vancomycine ou Teicoplanine                                                | Rifampicine + Ofloxacine ou Levofloxacine<br>Clindamycine + Ofloxacine ou Levofloxacine                                                                |                                                                                                                                              |
| Streptocoques non entérocoque            | Amoxicilline                                                               | Amoxicilline                                                                                                                                           | Clindamycine ou Fluoroquinolone anti streptococcique (Levofloxacine)                                                                         |
| Enterocoques                             | Amoxicilline + Gentamicine                                                 | Amoxicilline                                                                                                                                           | Avis infectiologique<br><i>Vancomycine + gentamicine**</i><br><i>Daptomycine + gentamicine</i>                                               |
| Entérobactéries hors <i>P.aeruginosa</i> | Cefotaxime<br>Ceftriaxone<br>Cefepime pour les entérobactéries du groupe 3 | Ofloxacine ou lévofloxacine en monothérapie (si la souche est sensible à l'acide nalidixique)<br><br>Avis infectiologique si entérobactérie résistante | Avis infectiologique                                                                                                                         |
| <i>Pseudomonas aeruginosa</i>            | Ceftazidime + Amikacine                                                    | Ciprofloxacine                                                                                                                                         | Avis infectiologique                                                                                                                         |
| Anaérobies                               | Amoxicilline si sensible<br>Ou Metronidazole                               | Clindamycine ou amoxicilline                                                                                                                           | Avis infectiologique                                                                                                                         |
| <i>Neisseria gonorrhoeae</i>             | Ceftriaxone ou Cefotaxime                                                  | Ofloxacine ou Levofloxacine                                                                                                                            | Ofloxacine ou Levofloxacine                                                                                                                  |

# Combien de temps Docteur les antibiotiques ?

**CLINICAL SCIENCE**

**Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial**

Ergys Gjika,<sup>1</sup> Jean-Yves Beaulieu,<sup>1</sup> Konstantinos Vakilopoulos,<sup>1</sup> Morgan Gauthier,<sup>1</sup> Cindy Bouvet,<sup>1</sup> Amanda Gonzalez,<sup>1</sup> Vanessa Morello,<sup>1</sup> Christina Steiger,<sup>1</sup> Stefanie Hirsiger,<sup>1</sup> Benjamin Alan Lipsky,<sup>2</sup> Ilker Uçkay<sup>1,3,4</sup>

**Handling editor:** Josef S. Smolen

**Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/annrheumdis-2019-215116).**

**Hand Surgery Unit, Hôpital Universitaire de Genève, Geneva, Switzerland**  
**Service of Infectious Diseases, Hôpital Universitaire de Genève, Geneva, Switzerland**  
**Division of Medical Sciences, University of Oxford, Oxford, UK**  
**Univision Belgium, Zurich, Switzerland**

**Correspondence to:** Dr Jean Uçkay, Univision Belgium, Zurich 8008, Switzerland; [jean.uckay@univision.be](mailto:jean.uckay@univision.be)

© 2019 and 118 are joint first authors.

Received 23 January 2019  
 Revised 1 April 2019  
 Accepted 1 April 2019

**Check for updates**

© Author(s) 2019. Re-use permitted under CC BY-NC. No commercial re-use, see rights and permissions. Published by BMJ.

**To cite:** Gjika E, Beaulieu J-Y, Vakilopoulos K, Gauthier M, Bouvet C, Gonzalez A, Morello V, Steiger C, Hirsiger S, Lipsky B, Uçkay I. Ann Rheum Dis. 2019;78:1114-21.

**ABSTRACT**

**Objective** The optimal duration of postsurgical antibiotic therapy for adult native joint bacterial arthritis remains unknown.

**Methods** We conducted a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. Excluded were implant-related infections, episodes without surgical drainage and episodes with a follow-up of less than 2 months.

**Results** We enrolled 154 cases: 77 in the 4-week arm and 77 in the 2-week arm. Median length of intravenous antibiotic treatment was 1 and 2 days, respectively. The median number of surgical drainage was 1 in both arms. Recurrence of infection was noted in three patients (2%): 1 in the 2-week arm (99% cure rate) and 2 in the 4-week arm (97% cure rate). There was no difference in the number of adverse events or sequelae between the study arms. Of the overall 154 arthritis cases, 99 concerned the hand and wrist, for which an additional subgroup analysis was performed. In this per-protocol subgroup analysis, we noted three recurrences: one in the 2-week arm (97% cure); two in the 4-week arm (96% cure) and witnessed sequelae in 50% in the 2-week arm versus 55% in the 4-week arm, of which five (13%) and six (13%) needed further interventions.


**Conclusions** After initial surgical drainage for septic arthritis, 2 weeks of targeted antibiotic therapy is not inferior to 4 weeks regarding cure rate, adverse events or sequelae and leads to a significantly shorter hospital stay, at least for hand and wrist arthritis.

**Trial registration number** NCT03615181.

**INTRODUCTION**

Native joint bacterial arthritis is frequent and usually associated with considerable morbidity, need for hospitalisation and substantial financial costs.<sup>1-3</sup> While the need for surgical drainage of these infections has been well established,<sup>4,5</sup> the ideal duration and route of administration of antibiotic therapy remains unknown. For almost 40 years, the recommended total duration of postsurgical systemic antibiotic therapy has been 3-6 weeks, with most clinicians prescribing 4 weeks for adults.<sup>6</sup> Unfortunately, this recommendation is based on expert opinion and individual experience, rather than on research studies. Furthermore, clinicians often treat bacterial arthritis at all anatomic sites in the same way, with no distinction between small and large joints.

In the current era of critical shortages of effective antibiotics, antimicrobial stewardship principles suggest that a shorter treatment duration and early switch to targeted oral agents could decrease antibiotic-related adverse events,<sup>7,8</sup> costs and possibly emergence of antimicrobial resistance. Retrospective studies,<sup>9</sup> reviews<sup>10</sup> and our own retrospective data<sup>11</sup> suggest that less than 2 weeks of targeted systemic antibiotic therapy after surgical drainage may be sufficient, especially for hand joints. In an attempt to provide an evidence base for antibiotic treatment for adult native joint arthritis, we undertook



Gjika E. Ann Rheum Dis. 2019;78:1114-21.

# Combien de temps Docteur les antibiotiques ?

Sauf que...

- 100 % patients drainage/synovectomie chirurgical
- 127 (81%) petites articulations (95 doigts, 28 MTP, 4 poignets)  
29 (19%) moyennes/grosses articulations (14 genoux, 7 épaules, 5 chevilles, 2 coudes, 1 hanche)
- 96 (61%) inoculations directs (morsures/griffures, post-traumatiques)  
6 (4%) hémocultures positives

**OPEN ACCESS**

**CLINICAL SCIENCE**

## Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial

Ergys Gjika,<sup>1</sup> Jean-Yves Beaulieu,<sup>1</sup> Konstantinos Vakilopoulos,<sup>1</sup> Morgan Gauthier,<sup>1</sup> Cindy Bouvet,<sup>1</sup> Amanda Gonzalez,<sup>1</sup> Vanessa Morello,<sup>1</sup> Christina Steiger,<sup>1</sup> Stefanie Hirsiger,<sup>1</sup> Benjamin Alan Lipsky,<sup>2</sup> Ilker Uçkay<sup>1,3,4</sup>

**Handling editor:** Josef S. Smolen

**Additional material:** is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2019-215116>).

**Supplemental material:** is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2019-215116>).

**Correspondence to:** Dr Ergys Gjika, Université de Genève, Genève, Switzerland; [ergys.gjika@unige.ch](mailto:ergys.gjika@unige.ch)

Received 23 January 2019  
Revised 1 April 2019  
Accepted 1 April 2019

**Check for updates**

© Author(s) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Gjika E, Beaulieu JY, Vakilopoulos K, Gauthier M, Bouvet C, Gonzalez A, Morello V, Steiger C, Hirsiger S, Lipsky BA, Uçkay I. Ann Rheum Dis 2019;78:1114-21.

**Abstract**

**Objective** The optimal duration of post-surgical antibiotic therapy for adult native joint bacterial arthritis remains unknown.

**Methods** We conducted a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. Excluded were implant-related infections, episodes without surgical drainage and episodes with a follow-up of less than 2 months.

**Results** We enrolled 154 cases: 77 in the 4-week arm and 77 in the 2-week arm. Median length of intravenous antibiotic treatment was 1 and 2 days, respectively. The median number of surgical drainage was 1 in both arms. Recurrence of infection was noted in three patients (2%): 1 in the 2-week arm (99% cure rate) and 2 in the 4-week arm (97% cure rate). There was no difference in the number of adverse events or sequelae between the study arms. Of the overall 154 arthritis cases, 99 concerned the hand and wrist, for which an additional subgroup analysis was performed. In this per-protocol subgroup analysis, we noted three recurrences: one in the 2-week arm (97% cure); two in the 4-week arm (96% cure) and witnessed sequelae in 50% in the 2-week arm versus 55% in the 4-week arm, of which five (13%) and six (13%) needed further interventions.

**Conclusions** After initial surgical drainage for septic arthritis, 2 weeks of targeted antibiotic therapy is not inferior to 4 weeks regarding cure rate, adverse events or sequelae and leads to a significantly shorter hospital stay, at least for hand and wrist arthritis.

**Trial registration number** NCT03615181.

**Introduction**

Native joint bacterial arthritis is frequent and usually associated with considerable morbidity, need for hospitalisation and substantial financial costs.<sup>1-3</sup> While the need for surgical drainage of these infections has been well established,<sup>4-6</sup> the ideal duration and route of administration of antibiotic therapy remains unknown. For almost 40 years, the recommended total duration of post-surgical systemic antibiotic therapy has been 3-4 weeks, with most clinicians prescribing 4 weeks for adults.<sup>7</sup> Unfortunately, this recommendation is based on expert opinion and individual experience, rather than on research studies. Furthermore, clinicians often treat bacterial arthritis at all anatomic sites in the same way, with no distinction between small and large joints.

In the current era of critical shortages of effective antibiotics, antimicrobial stewardship principles suggest that a shorter treatment duration and early switch to targeted oral agents could decrease antibiotic-related adverse events,<sup>8,9</sup> costs and possibly emergence of antimicrobial resistance. Retrospective studies,<sup>10-12</sup> reviews<sup>13</sup> and our own retrospective data<sup>14</sup> suggest that less than 2 weeks of targeted systemic antibiotic therapy after surgical drainage may be sufficient, especially for hand joints. In an attempt to provide an evidence base for antibiotic treatment for adult native joint arthritis, we undertook

**Key messages**

**What is already known about this subject?**

- The treatment of a septic arthritis requires a combination of at least one low-dose intravenous and a long-lasting antibiotic administration.
- Usually, this initial antibiotic administration is parenteral during the first 2 weeks.

**What does this study add?**

- According to our randomised controlled trial, and at least for hand and wrist septic arthritis, total post-surgical antibiotic therapy can be limited to 2 weeks.
- Likewise, the initially systemic (and often empirically parenteral) antibiotic therapy can be switched to targeted oral medication after few days (1-2 days parenterally only).

**How might this impact on clinical practice or future developments?**

- Future patients with septic (hand and wrist) arthritis and a good evolution after surgical drainage might profit from significantly less antibiotics.
- This might limit potential adverse events, costs and complications of (parenteral) antibiotic therapy.

**BMJ**

**eular**

*Combien de temps Docteur les antibiotiques ?*

- . 3 à 6 semaines (selon bactérie, rapidité de l'évolution, stade de prise en charge)
- . 7 jours pour *Neisseria sp.*

Etude SHASAR (3 *vs* 6 semaines d'antibiotiques) (PHRC national)

Lundi 9 Décembre 2019

16:30 - 17:30

Infections ostéo-articulaires

Session scientifique

Salle 5

**16:30** **Y'a-t-il un intérêt à l'ensemencement systématique d'un flacon d'hémoculture au lit du malade pour le diagnostic microbiologique d'arthrite septique ? Etude transversale monocentrique sur 224 arthrites aiguës**

O.84

**O. Berthoud (Rennes)**, G. Coiffier (Rennes), C. Goussault (Rennes), J.-D. Albert (Rennes), C. Bendavid (Rennes), A. Jolivet-Gougeon (Rennes), P. Guggenbuhl (Rennes)



**16:40** **Pose de prothèse de genou (PTG) ou de hanche (PTH) après ou au cours d'une arthrite septique : analyse rétrospective de 53 cas pris en charge dans un Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAC)**

O.85

**E. PORTIER (Paris)**, V. Zeller (Paris), S. Godot (Paris), Y. Kerroumi (Paris), B. Heym (Paris), V. Meyssonier (Paris), C. Béal (Paris), S. Marmor (Paris), P. Chazeraïn (Paris)



**16:50** **Intérêt du TEP-scanner dans le bilan d'extension septique des endocardites infectieuses : Focus sur les atteintes musculosquelettiques**

O.86

**B. Hugues (Créteil)**, B. Emsen (Créteil), J. Ternacle (Créteil), A. Moussafeur (Créteil), X. Chevalier (Créteil), R. Lepeule (Créteil), R. Huguet (Créteil), A. Fiore (Créteil), M. Abulizi (Créteil), F. Eymard (Créteil)



**17:00** **L'infiltration intra-articulaire de corticoïdes est-elle délétère au cours d'une arthrite de Lyme ? Etude rétrospective multicentrique sur 52 patients**

O.87

C. Corre (Rennes), **G. Coiffier (Rennes)**, M. Ferreyra (Vannes), B. Le Goff (Nantes), X. Guenoc (Saint-Brieuc), J.-D. Albert (Rennes)



**17:10** **Diagnostic et prise en charge thérapeutique des bursites septiques : à propos de 246 cas**

O.88

**K. NGUYEN (Lille)**, P. Coquerelle (Beuvry), H. Migaud (Lille), E. Senneville (Tourcoing), E. Houvenagel (Lomme), R. M. Flipo (Lille), B. Cortet (Lille)



**17:20** **Place de l'échographie cardiaque dans la prise en charge d'une infection ostéo-articulaire bactérienne sans matériel**

O.89

**M. BEAUFRERE (Caen)**, J. Michon (Caen), R. Verdon (Caen), E. Fiaux (Rouen), V. Rasoldier (Rouen), M. Etienne (Rouen), C. Marcelli (Caen), O. Vittecoq (Rouen), G. Avenel (Rouen)

